Search company, investor...

Executives

6

Forty Seven Management Team

6 Team Members

Forty Seven has 6 executives. Forty Seven's current President is Mark A McCamish.

Name

Work History

Title

Status

Mark A McCamish

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Mark A McCamish

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Forty Seven to Competitors

OncoResponse Logo
OncoResponse

OncoResponse develops therapeutic antibodies for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). It develops cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system. The company was founded in 2015 and is based in Seattle, Washington.

I
ImmunoMet Therapeutics

ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop anti-tumor and immuno-oncology therapies. The company develops a molecule that targets the oxidative phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and selects cancer cells. It was founded in 2015 and is based in Houston, Texas.

Immune-Onc Therapeutics Logo
Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage company that focuses on the development of novel myeloid checkpoint inhibitors in the healthcare and biotechnology industry. The company's main offerings include the development of immunotherapies for cancer, harnessing the body's own immune system to fight against disease, with a particular focus on blood cancers and solid tumors. Immune-Onc primarily sells to the healthcare industry, specifically in the field of cancer treatment. It was founded in 2016 and is based in Palo Alto, California.

F
Fortis Therapeutics

Fortis Therapeutics is a company focused on the development of novel, first-in-class therapeutics in the healthcare and biotechnology industry. The company's main offerings include precision therapies that target CD46 proteins in cancer cells, while sparing normal tissues. The company primarily serves the healthcare industry, specifically the oncology sector. It was founded in 2016 and is based in La Jolla, California.

Macrophage Pharma Logo
Macrophage Pharma

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. The Company's technology platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner to activate the body's natural immune system to fight cancer.

E
Epsilogen

Epsilogen focuses on the development of immunoglobulin E (IgE) antibodies. The company's main offerings include the development of IgE-based drugs that are designed to treat solid tumors, leveraging the potency, enhanced tumor access, and long tissue half-life of IgE. It primarily serves the oncology sector of the healthcare industry. Epsilogen was formerly known as IGEM Therapeutics. It was founded in 2016 and is based in London, United Kingdom.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.